<SEC-DOCUMENT>0000200406-13-000052.txt : 20130614
<SEC-HEADER>0000200406-13-000052.hdr.sgml : 20130614
<ACCEPTANCE-DATETIME>20130423151245
<PRIVATE-TO-PUBLIC>
ACCESSION NUMBER:		0000200406-13-000052
CONFORMED SUBMISSION TYPE:	CORRESP
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20130423

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			JOHNSON & JOHNSON
		CENTRAL INDEX KEY:			0000200406
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				221024240
		STATE OF INCORPORATION:			NJ
		FISCAL YEAR END:			1212

	FILING VALUES:
		FORM TYPE:		CORRESP

	BUSINESS ADDRESS:	
		STREET 1:		ONE JOHNSON & JOHNSON PLZ
		CITY:			NEW BRUNSWICK
		STATE:			NJ
		ZIP:			08933
		BUSINESS PHONE:		732-524-2455

	MAIL ADDRESS:	
		STREET 1:		ONE JOHNSON & JOHNSON PLZ
		CITY:			NEW BRUNSWICK
		STATE:			NJ
		ZIP:			08933
</SEC-HEADER>
<DOCUMENT>
<TYPE>CORRESP
<SEQUENCE>1
<FILENAME>filename1.htm
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using WebFilings 1 -->
		<!-- Copyright 2008-2013 WebFilings LLC. All Rights Reserved -->
		<title>April 2013 Comment Letter</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<a name="s6EEA7D51FB5F1E863BCC36C7CC30D130"></a><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;"><img src="jjlogoforwebfilinga07.jpg" style="height:44px;width:238px;"></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:93.359375%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td width="50%"></td><td width="50%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:11pt;"><font style="font-family:Arial;font-size:11pt;font-weight:bold;">Stephen J. Cosgrove</font></div><div style="font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Vice President</font></div><div style="font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Corporate Controller</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">One Johnson &amp; Johnson Plaza</font></div><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">New Brunswick, NJ 08933</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">April 23, 2013</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Via EDGAR</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Mr. Jim B. Rosenberg</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Senior Assistant Chief Accountant</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">U.S. Securities and Exchange Commission</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Division of Corporation Finance</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">100 F Street, NE</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Washington, DC 20549</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Re:&#160;&#160;&#160;&#160;Johnson &amp; Johnson </font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Form 10-K for the Fiscal Year Ended December 30, 2012 </font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Filed February 22, 2013 </font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">File No. 001-03215</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Dear Mr. Rosenberg:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Johnson &amp; Johnson is submitting this letter in response to the written comments of the staff (the &#8220;Staff&#8221;) of the Securities and Exchange Commission (the &#8220;Commission&#8221;), dated March 28, 2013, with respect to Johnson &amp; Johnson's Form 10-K filed with the Commission on February 22, 2013 for the fiscal year ended December 30, 2012 (the &#8220;Form 10-K&#8221;) (SEC File No. 001-03215).</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Set forth below is the heading and text of the comment followed by our response:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Business </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Patents and Trademarks, page 2 </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">1.</font><font style="font-family:inherit;font-size:10pt;"></font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">We note your statement on page 2 that you believe the patents related to REMICADE</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174; </sup></font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">are material to the company. Please amend your disclosure to explain: </font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font><font style="font-family:inherit;font-size:10pt;"></font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">whether you own or license these patents, and from whom you license them, if applicable; </font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font><font style="font-family:inherit;font-size:10pt;"></font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">the material jurisdictions in which you hold these patents; and </font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font><font style="font-family:inherit;font-size:10pt;"></font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">the expiration dates of these patents. </font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">In addition, please describe your anticipated response to the loss of protection, including for example, any plans to apply for exclusivity extensions and the basis for such actions. If you do not intend to take any such actions please disclose that as well.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Response:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Johnson &amp; Johnson follows the guidance of Item 101(c)(1)(iv) of Regulation S-K with regard to patents.  The Company's practice has been to disclose material products supported by patents.  The expiration dates of such associated patents are also disclosed when expiration is scheduled to occur within two years of the annual filing on Form 10-K. Additionally, quarterly filings include disclosures of the potential impact to revenue for those material products subject to patent expiration within the next year. </font></div><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><a name="s6EEA7D51FB5F1E863BCC36C7CC30D130"></a><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We confirm that in future Annual Reports on Form 10-K, beginning with the Annual Report on Form 10-K for the fiscal year ended December 29, 2013, the Company will expand the disclosure in Item 1 - BUSINESS, Patents and Trademarks, to include the following, updated as necessary:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">There are two sets of patents related to REMICADE</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">&#32;(infliximab).&#160;The first set of patents is co-owned by Janssen Biotech, Inc., a wholly-owned subsidiary of Johnson &amp; Johnson, and New York University Medical Center (NYU). Janssen Biotech, Inc. has an exclusive license to NYU's interests in the patents. &#160;Patents have been granted in the United States, certain countries in the European Union (certain of these patents have been extended by Supplementary Patent Certificates), and Australia. These patents expired in Canada in March 2012.  However, sales in Canada have not been impacted as a generic competitor has not entered the market. &#160;In the United States, the patent expires in September 2018. &#160;In certain countries in Europe the patent has been extended to February 2015 (Germany, Spain, United Kingdom, Sweden, Austria, Belgium, Switzerland, Denmark, France, Greece, Italy, Luxembourg and The Netherlands). In Australia, the patent expires in March 2017.&#160; </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The second set of patents related to REMICADE</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174; </sup></font><font style="font-family:inherit;font-size:10pt;">was granted to the Kennedy Institute of Rheumatology in the United Kingdom in Europe, Canada, Australia and the United States. Janssen Biotech, Inc. has an exclusive license to these patents which expire in 2017 outside of the United States and 2018 in the United States. The validity of these patents has been challenged and is currently in litigation.&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Johnson &amp; Johnson does not expect that any additional extensions will be available for the patents related to REMICADE</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition to competing in the immunology market with REMICADE</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">, the Company is currently marketing STELARA</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">&#32;(ustekinumab) and SIMPONI</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">&#32;(golimumab), next generation immunology products with remaining patent lives in excess of 10 years.&#160; </font></div><div style="line-height:120%;text-align:left;padding-left:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exhibit 13 </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Notes to Consolidated Financial Statements </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Note 20. Business Combinations and Divestitures, page 50 </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">2.</font><font style="font-family:inherit;font-size:10pt;"></font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Throughout your note, you reference to purchase price allocations. Please tell us how using purchase price allocation complies with the acquisition method as described in ASC 805.</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Response:  </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In response to the Staff's request to explain how using purchase price allocation complies with the acquisition method as described in ASC 805, please find additional details as follows:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Johnson &amp; Johnson follows ASC 805 when accounting for business combinations using the acquisition method.&#160; As a result of applying the acquisition method, Johnson &amp; Johnson measures the identifiable assets acquired, the liabilities assumed, and any non-controlling interest in the acquired business at the acquisition date fair values.&#160;Any excess of the consideration transferred over the assigned values of the net assets acquired is recorded as goodwill.  When appropriate, independent third party valuation firms are engaged to value the net assets acquired. &#160;In accordance with US GAAP, fair value is determined by the price that would be received from the sale of an asset or paid to transfer a liability in an orderly transaction between market participants.&#160;&#160; In accordance with ASC 820, Johnson &amp; Johnson used&#160;the income approach as the basis for the purchase price allocations referenced in Note 20. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">3. </font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Please explain to us your basis for concluding that the estimated useful life of the Synthes amortizable intangibles was a weighted average of 21 years. Please breakout this analysis between customer relationships and patents and technology. </font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:24px;text-indent:-24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Response:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In response to the Staff's request to explain the basis for concluding the estimated useful life of the Synthes amortizable intangibles, please find additional details as follows:</font></div><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><a name="s6EEA7D51FB5F1E863BCC36C7CC30D130"></a><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Customer Relationship ($9.9 billion) intangible lives were determined using the projected customer retention period based on historical experience.&#160;Synthes has a broad product portfolio including trauma, spine, cranio-maxillofacial, biomaterials and power tools.  An analysis was performed to determine the lives for each of the customer relationship assets in the distinct product areas.&#160;  The calculations to determine useful lives included attrition rates and discounted future cash flows by product area. This analysis resulted in a weighted average life of 22 years for the Customer Relationship assets.  </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Patents and Technology ($1.5 billion) intangible lives were derived based on technology obsolescence rates that are commensurate with the nature of the Synthes businesses.&#160; New product introductions are predominantly incremental enhancements to existing platforms and are infrequently transformational.  An analysis was performed to determine the lives for each of the Patents and Technology assets in each distinct product area.  The calculations to determine useful lives included assumptions on technology obsolescence and discounted future cash flows by product area.  This analysis resulted in a weighted average life of 18 years for the Patents and Technology assets.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A weighted average of the values and lives ascribed to the Customer Relationship and Patents and Technology intangible assets results in a 21 year weighted average life.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As requested, we acknowledge that:</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font><font style="font-family:inherit;font-size:10pt;"></font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Johnson &amp; Johnson is responsible for the adequacy and accuracy of the disclosure in the filing;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font><font style="font-family:inherit;font-size:10pt;"></font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Staff comments or changes to disclosure in response to staff comments do not foreclose the Commission from taking any action with respect to this filing; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font><font style="font-family:inherit;font-size:10pt;"></font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Johnson &amp; Johnson may not assert staff comments as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Please do not hesitate to contact me at 732-524-1831 with any questions or comments you may have.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:93.359375%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td width="50%"></td><td width="50%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Sincerely,</font></div><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/ Stephen J. Cosgrove</font></div><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Vice President</font></div><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Corporate Controller</font></div><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Chief Accounting Officer</font></div><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">cc: Dominic J. Caruso</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>jjlogoforwebfilinga07.jpg
<TEXT>
begin 644 jjlogoforwebfilinga07.jpg
M_]C_X``02D9)1@`!`0$`>`!X``#_VP!#``@&!@<&!0@'!P<)"0@*#!0-#`L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+#`Q-#0T'R<Y/3@R/"XS-#+_
MVP!#`0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P``1"`#7!&0#`2(``A$!`Q$!_\0`
M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4%
M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!
M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$"
M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#W^BBB@`HH
MHH`3/%)CTI:R-9\0:;H5OYM]<*A/W4SEF^@_R*3:2NQPA*<E&"NS6/2DSBO(
MM8^*>HW+-'I<"6L7022`/(??'0?K7+7/B37+B7=-JEZ''82L@'X#`K)UXK8]
MFCD6(FKS:C^9]$#I161X9GGN/#>GS7,ADF>W1V=NIR,Y-:U:IW5SQYQY9.+Z
M#J***9(4444`%%%%`!1110`4444`)114-Q<16L#S3R+'$@+,SG``]2:`2OHB
M48-!XKS'6OBF(YFCT>U615X\Z?(!^BC!Q]3^%9]C\5]4CF'VZSMIH<\^4"C`
M>V2163K0N>G')\7*'-R_*^IZ_1@$5FZ1JUKK>GQWMFY,;]B,$$=01V-:5:)W
MU1YLHRA)QDK-"T444Q!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444
M`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`
M4444`%%%%`!1110`4444`%%%%`!1110`WM0>E0W-U!:6[3W$J1Q*,L['``^M
M>?:Y\4[>!FBT>#SV''G29"?@O4_I4RG&.YT8?"5L0[4XW_(]'Z"C.>F*^?[_
M`,8^(=0):74IXTR<+"?+'T^7&?QKO/A=?:A>V^H?:[F6>)&3RS*Y8J2&W<G_
M`(#41JJ4K6.[$Y14P]!UIR6G0]&HHHK4\D****`"BBB@`HHHH`****`"BBB@
M!**.E<9XE^(%CH4KVD"_:[Q?O*K85/\`>;U]A^E3*2BKLUH4*E>?)35V=D,4
M5XW_`,+4USSL_9[/R\_=V-T^NZNZ\*>-+7Q(C1,GD7B#+1$Y!'JI[THU8R=C
MJQ&5XG#PYYK3R.LHHHJS@"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`H
MHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BB
MB@`HHHH`****`"BBB@!">:**\_\`'GC4Z8K:9ITG^F./WCK_`,LE/_LQ_2IE
M)15V;X;#U,145.FM2?QAX]AT4O8V!$]_C#-U6'Z^I]OSKS;3--U;QCK17S7F
ME;YIIY#D1K[_`-`*SK"QNM6U&&TMU,EQ.^!D_F2?3N:]\\.Z%:^']*CL[8`D
M?-+)CF1NY-<T5*K+78^BKRHY52Y::O4?7]?3LBCHOA31_#=J9%C629%+27,H
M!;U./[H]A7C.KWLFN^(;BY5?FN9L1K[=%'Y8KUKXD:M_9WA=X$.);QO*'^[U
M8_EQ^->6>$K47GBS3(3R//5R/9?F_I3JVNH1#*5/V53%U'=Z[]EJSWVTMUM;
M2&%/NQHJ+]`,5/0.E%=6Q\NVV[L6BBB@04444`%%%%`!1110`4444`-SS[5X
MY\1?%+ZEJ#:3:R$6ELV)"#Q)(/Z#^?X5Z+XOU@Z)X<NKM&Q,5\N+_?;@'\.O
MX5X"2222<D]2:YZ\_LH^BR'!J<G7FMM%Z]S;\*:`WB+6TM"66!1YDSKU"#L/
M<\"M?Q]X7M/#TUG)8HRPSJRL"Q;#+CN?7/Z5TGPGL@FFWU\1\TLPB!/HHSQ^
M+?I3?BY_QXZ9_P!=7_D*CD2I<QU2QU269JE%^ZM+?(R_A3J4D6KW6G$YBFB\
MT#T92!^H/Z"O7<5X?\-?^1SM_P#KG)_Z#7MX.:UH.\3R\\@HXNZZI/\`0=11
M16QXX4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%
M%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`444
M4`%%%%`!1110`WI6+K_B2Q\/6/GW3Y=L^7$OWG/M_C1XD\06OA[3'NI_F<_+
M%&#@NWI]/4UX5JVK7>M7\EY>2;W?@`?=0=E`["L:M7ET6YZV698\4^>>D%^)
MH:UX@U;Q9J"1R;BK/B"UBSM![<=S[_RKOO"_PXMK&);K6$2YN3R(CRD?U_O'
M]/YTOP\\)II]JFK7L?\`I<RYA5A_JT/?ZD?I^-=Q>745C937,S;8H49V/L!D
MU-.G?WYG1C\?ROZMA=(K33J>4_%#4XY=1MM)@"B.T3>X4#`9L8'M@8_.NG^%
MUG]G\+&<CFYF=P?887^8->1ZC>RZEJ-S>S']Y-(7/MD]/PZ5[QX1MOLGA33(
MMNT^0K$>A8;C^IJ:?O5+F^9P^KX&%#K?7\W^)NT445U'S04444`%%%%`!111
M0`4444`%%%(Q"J23@"@#C/'OBAM`TT6]H^+ZYR$/]Q>[?7L/_K5XNJR7$X50
MTDLC8`ZEF)_G6KXIUAM<\0W5[NS%NV0CT0<#\^OXU<\!V(O_`!A9!@"D1,K9
M_P!D9'_CV*XIR<Y'VV#P\<!A'4:UM=_Y'4:K\/++3O!TUSN9M1AB\UY-W!QR
MR@=,8SCO7!:)J+Z5K5I?(Q7R906QW7HP_$9%>\^)P#X5U8$9_P!#E_\`0#7S
MO558J+5CGRBM/%4:BK.^OYH^G5(900<YIU5K+=]B@W_>\M<_7%6*ZD[H^2DK
M.PM%%%,04444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444
M`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!112,0
MJDF@#FO&/B)/#FC/*FUKN7Y($/\`>_O'V'^`[UX3--)<3R33.7ED8L[,>23U
M-;WC+7CK_B":9&S;1'RX0#QM'\7XGG\JR=+L9-3U2VLHOO3RJF?0$\G\!S7%
M4GSRL?;99A(X3#\\_B>K_P`OD>F_##P_]GLGUF=/WL^4AR.50=3^)_0>]>C5
M7M;:*SM8K:!0L<2!$`[`#%232K#$\CG"JI8GV%=48J$;'R6*KRQ-:4WUV].A
MXQ\3-4^W>)OLJ-F.S0)_P(\M_0?A3/AI`)O&43D9\F*1Q[<;?_9JYB_NWO\`
M4+B[?.Z:5I#DYQDYQ7:?"B//B*ZES]VU*XQZNO\`A^M<L7S33\SZVO3^KY<X
M+I&WW[GL5%%%=I\2%%%%`!1110`4444`%%%%`!1110!Y7\6M0S-8:<I&`K3.
M/K\J_P`FKS2NJ^(ET;GQI>+_``PA(U_!03^I-<K7!4=Y-GWV5TO9X2"\K_?J
M>Y?#>+RO!5FV,&1I&/\`WV1_2N=^+DP$.EP8^8M(_P!,;1_7]*Z[P4NSP=IB
M^L(/YDFO./BC??:/$R6H((MH5!QV9OF/Z;:VGI21\_@8NIFCEV<G^:&_"V$R
M>+&DQQ';NV<=,E1_6O:17F?PEL2L&H7[`X=EB3CTY/\`,?E7I?05=!6@<V<U
M%/%RMTLAU%%%;'E!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%
M%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`444
M4`%%%%`!1110`4444`)D57NKF&SMI;B9PD4:EG8]`!UJ?VKS3XI:\8XXM$A;
M!D`EG(_NY^5?Q()_`5,Y<L;G3A,-+$UHTEUW]#A_$_B&;Q%K$EV^Y8%^2",_
MP)_B>I_^M5SP-H']NZ^@E3=:V^)9O1O[J_B?T!KF:]N^'6D#3?#4,[#$MV?.
M;_=/W1^7/XUR4X\\M3ZW,:L<%A.2GIT7]?UJ=?PHQ7$?$[5/L?AL6:-B2\<)
MP?X%Y;^@_&NW->-?%*_-QXECLPP*6L0!'HS?,?TVUT5G:!\WE-'VN+C?9:_=
M_P`$XA5+,%4$L3@`=37TO;1"&UBB'1$"_D,5\Y:6GF:O8IC.ZXC7'KEA7TDO
M05GA^IZ?$<O>IQ]?T'4445TGS04444`%%%%`!1110`4444`(>:Y[QIJ/]F^%
M+^=3B1H_*3'7+';^F2?PKH,UY]\6;@QZ'9P`X\RXW'W"J?\`$5%1VBSKP-)5
M<3"#[_EJ>1UWWPH@#Z]>3GK';[1_P)A_A7`UZ5\(E_TC57QT6/GZEO\`"N.E
M\:/L,VERX.?]=4=SXNE$7A+5&)QFV=?S&/ZUX!;PM<7,4"?>D<(/J3BO9/B;
M>_9O"C09.;F5(QCT!W'_`-!_6O-_!5A_:/B[3XRN423S6]@GS?S`'XUK6UG8
M\[)OW6#G6?F_N1[XBA8U4=`,4^@=**ZCY4****`"BBB@`HHHH`****`"BBB@
M`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"
MBBB@`HHHH`****`"BBB@`HHHH`2N8\=ZM_9/A6Z=&Q-,/)CYP<MUQ]!D_A73
M`Y%>6_%N\/FZ=9`\`/*P_(#^35%5V@SMRVBJV*A%[;_=J>:5W/PNT\7/B26[
M905M8B5/HS<#]-U<-7K7PFM?+T:]N2N#+.$SCJ%4?U8_K7)25YH^MS>K[/!R
MMUT^_P#X!Z(.M<]XUNA9>$-3DW8+1&,'W8[?ZUT-</\`%*Y\GPJL0ZS7")^`
M!;^@KKJ.T6?'8*'M,1"/FCQFO0?A-_R&K[_K@/\`T(5Y]7?_``G=1KU[&3\Q
MML@>P89_F*XZ?Q(^SS7_`'.?I^I[!1117>?!A1110`4444`%%%%`!1110`4'
MI10>AH`^>/%<WG^*]5?GBY=.?]DX_I6/6EXB_P"1GU7_`*_)O_0S6;7GRW/T
M;"JU"*\E^1[]X2E2+P5ITDA"HML"2>P%>'ZQ?MJVLW=\V?W\K,H/4#/`_`8%
M=YK&NC3?AEIEA$X%Q>P!,#LG\1_'I^)K`\`:"=9\0QSR+FUM")9">C-_"OY\
M_0&M9/FY8H\3`PCAE6Q53N[?)_J]#U;PEI)T7PW9VCC$H7?)_O-R?RSC\*W>
MU)GM1G-=:5E8^6J5'4FYRW>HZBBB@D****`"BBB@`HHHH`****`"BBB@`HHH
MH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@
M`HHHH`****`"BBB@`HHHH`****`"BBB@"-V6-"S$``9)/85\ZZ[J3:QKEYJ#
M9Q-(2H/91PH_("O;?&MX;#PCJ$ZDAFC\I2.N7(7^M>`URXAZI'U'#U!6G6?I
M^K+.G6C:AJ=K9KG,TJQY';)QFOI&&)(84C0;550`!V`KP[X>6HNO&=F3]V%7
ME/X*0/U(KW6JPZT;.?B"K>M&GV5_O_X8:>.:^>/$MT;WQ-J4Y[SN%^@.!^@%
M?0=S*(;6:4]$0M^0S7S0[L[L['+,<D^IHQ#V1?#T/?G/T7]?<7M$_P"0_IW_
M`%\Q?^ABOHX=!7S?H[;=;T]L9VW,9Q_P(5](#H*,/U%Q%_$AZ,=11170?.A1
M110`4444`%%%%`!1110`E>5_%ULW&DKD<+*<?4K_`(5ZH*\F^+?_`"$=-_ZY
M/_,5E6^`]3)E_MD?G^1YU7IWPA^]K'TA_P#9Z\QKT#X;ZE#I.GZ]>W#8BA2)
MCSU^_@#W)P/QKFI.TTSZ;.(N6$E%;NWYH;\4]5%SK5OIT;96U3<X!_C;!_D!
M^=:7PHT@JEWJTB_>_<19';@L?_01^!KSYVN_$&N$@>9=7DW`[98_R'Z`5[_H
MNFQ:1I%K80?<A0+G&,GN?Q.36M-<\^8\O,9K"8*&%CN]_P!?O9HT445TGS(4
M444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!11
M10`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`E>*_%!RWB
MX*>BVR*/S8_UKVJO$_B?_P`C@W_7O'_6L*_PGLY%_O?R9QM>W?#2/9X-MVX^
M>21O_'L?TKQ&O<?AL0?!=IS_`!R?^AFLJ'Q'L9__`+LO5?DSK>U><_%M\:9I
M\?/S3,WMPO\`]>O1J\W^+O\`QY:9_P!=7_D*WK?`SY[*E?&0^?Y,\IKM?A:^
MWQ:ZY^];.O\`X\I_I7%5U'P\G,/C6R4=)%=#_P!\$_S`KDI_$C[',8\V%J+R
M9[O1117H'Y\-HSP>*AN+F&T@>:XD6.-!EG8X`'N:\R\3?$QG+6FAY5>C73KR
M?]T'^9_*IG-0W.K"X*MB9<M-?/HCT#5->TS1H?,OKR.'(^52<LWT4<FN;@^)
MFD7.IQ6<-M=N976-7"#&2<#C.:\=FGEN96EGE>61SEG=BQ/U)KT_X<>$UAA7
M7+U`9'&;9#_"O]_ZGM[?6L%5E.5D>Q7RO#8.@YUFY/ITU.ZU+6=/T>W\Z_NH
MX$[9/+?0#D_A6`OQ*\-M*$^TRJ/[YA;'^/Z5Y7XJU2?5?$5W+*Q*1RM%&F>$
M53@#^M4H='U*XLC>PV-Q);*2#(B$KQUI2KROH:T,DH^R4Z\G=^:1]#V=]:ZA
M;+/9SQSQ-T=&R*L_Q=*^>-`\0WOAV_6YM7)C)_>PL?ED'H??T/:O>=)U2WUC
M38+ZU;,<HR`>JGN#[@\5K3J<VG4\K,<MGA))IWB^OZ,T*#T-%-8A5))``Y)-
M:GFH^=/$7_(S:K_U^3?^AFLVM#7G23Q#J;HZNKW<K*RG((+G!!K/KSY;GZ/A
M_P"#'T1;7[9JMU;6RYFFVK#$@'0#H!^OZU[MX8T&+P[H\=DA#2GYYG`^\YZ_
MAV'TKF_AQX7ALK*/6IRKW%PF8L=$0_U->@9/-=-&G9<S/E,XQRJR]A3^&._F
M_P#@!VZ5S>N>-='T%S#<3&2X`R885W,/KV'XFJOCKQ2-`TOR;<C[=<`K%_L#
MNW^'O]*\2=WDD:21F9V)+,QR23W-%6KRNR#+,I^LQ]I5TCT\_P#@'M&E?$C1
MM3NDMG\ZU=SA#,H`)],@G'XUV0P1D=*^8Z]^\%ZA)J?A.PN)6)EV%')ZDJ2N
M?QQFG2JN3LQ9MED,*E.GL]#H:***V/$$)P.:Y/6O'VBZ/,\!E>XG3AHX%#;3
MZ$D@9_&J?Q$\3MI&GK86DFV[N0<L#S&G<_4]!^->,UA4JN+M$][+,H6)A[6K
MMT7<]KTCXC:-JMVEJ1-;/(=J><H`8^F03C\<5V0P0,5\Q=#7T#X0U!]4\+6%
MU*Q:1H]KL>I925)_2G2J.3LR,VRR&%4:E/9Z&Z:.U':N9\9>)5\.Z0SH0;N7
M*0(?7NQ]A_AZUK)I*[/'I4I59JG!:LDUSQCI&@'R[F<O<8SY,*[FQ[]A^)%9
M-A\3]$N[A894N+8,<!YE&W\2"<5X[//+<SO//(TDLC%G=CDDU'7*Z\KGUE/(
M*"A:;;?<^FT<2(&4Y!'!%/KC_AOJ+W_A6-)6+/;2-#D]<#!'Z,!^%=@*ZHRY
ME<^5KT71J2IOHPS368*I)(`'))I:Y/Q_KG]C^'9$1\7%UF&/!Y`/WC^`_4BE
M*7*KBH4I5JD:<=V5O#GCM-<\17&FF%4CPQMY`W+A3W]R.?PKM<=Z^;=,U";2
MM3MKZ#_602!P/4=Q^(R/QKZ(T^]AU&P@O+=MT4R!U/L:SHS<M&>GF^`6&G&4
M%[K_`#1<HHH)P.:V/(&D9%(Q55Y(`%<;XB^(6G:*7MK4_;+P<%4/R(?]IO7V
M'Z5Y?K'BO6-<9A>7;"(_\L8OD0?AW_'-8SK1CHM3U<'E%?$+F?NQ\_\`(]BU
M#QKH&FDB;4(FD!P4B^<Y_#I^-83_`!6T=9,+:7K+G[VQ/T^:O(*[KX>^$EU:
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MGCGBH;FY@L[=[BXE2*)!EG8X`%>2^+OB%-J):RT=WAM>CS='D^G]T?J:J=10
M6IRX/`U<5/E@M.KZ([G6/'6AZ/(T,EP9IU^]'`-Y'L3D`'VS69:?%/1)YA'-
M%=0*?^6C(&4?7:2?TKQRBN9UY7/I89!AE&TFV^Y],07$5S`DT+J\3J&5E.00
M>A!J:O/OA5?O<:+<V3ON^S2`H/[JL,X_,-^=>@UU0ES*Y\MBJ#H5I4GT#O6-
MK7B33=!@5[ZY",WW8P-SM]`/Y]*DU[6;?0M*FOIR2$&%4=68]`*\!U+4KG5[
M^6\NY#)+(<GT`[`>@%9U:O+HMSORS+'BVY2TBOQ/5H/BKHDDRI);WL:'_EHR
M*0/J`Q/\Z[6TO(+ZVCN;:59(I!N5U/!%?-->F?"?4W,E[ICOE0HFC4GISAL?
MFM33K-RLSMS/)Z="C[6C?3<]3HHHKH/G`HHHH`****`"BBB@`HHHH`X;XI3>
M5X41.?WMPJ<?0M_[+7C->P_%=2?#-M@$XO%)QV^1Z\>KCK?&?9Y"O]E^;.Z^
M%2%O%%Q)CA;5OP)9/_KU[)7CWPHD`\07<6#\UMNS]&'^->PUM1^$\+.[_7'Z
M(R_$DIA\-:G(I`*VLA&?7:<5\ZU]"^+?^13U7_KVD_\`037SU6>(W1ZO#J_=
MS?G^A+;R^1=13<_NW#<=>#FOIA?NCZ5\Q5])Z=+YVFVTO]^)&_,"C#[LRXBC
M_#EZ_H7***,XKJ/F1M0W-U;V<#37,T<,:\EW8`#\37)^)_'UCH6^UM0+J^'!
M4'Y(_P#>/]!^E>2ZMKNHZY/YM_=-)C[J#A$^B]!6,ZRCHCU\%E%;$+GE[L?Q
M?HCU>_\`B9H-HY2%KBZ(."8DPOYL1^E=%IVL6VIZ+'J@S#;R*6/G84J`2#GM
MVKQGP9X9;Q'JVV7<ME#AIF'?T4>Y_EFND^)^H_919:%;#RK=(Q(T:C`(R54?
M0;3^E3&K*SDSHKY;A_;PPM)OFW;[+_,ZF?XC>&[>8Q_:Y)<'&Z*)BOY]ZU=)
M\2Z3K:?Z!>QRN!DH<JX_X">:\"L=.O-2E,5E;23N!DJBDX'J?2D'VO2[T'$U
MM=1-D9!1T-0J\KZG74R+#M<M.;YOE^1]+9H[UQ_@GQ8/$5DT%SM6^A`W@<!Q
M_>']1_C785TQDI*Z/F:]&=&HZ<UJ@->3?%O_`)"6F_\`7)_YBO637D?Q8ECD
MU2P175G2)MR@Y*Y(QD=JSK_">CDO^^1^?Y'GM3)=2QVDMJC$12LC2*/XBN['
M_H1J&NK\!^&4\0ZK(]P0;6TVM(G>0G.U?IP<_P#UZY$FW9'V.)JPHTG4J;+^
ME^)U7PT\,&WA&N7:8DE7%NI_A0]6_'M[?6O2.WI34544*H`4#``Z"JFIZA!I
M=A/?7+!88ERWOZ`>Y/%=T8J$;'P6)KU,77<WN]E^2(]5UFPT6V-S?W*PH>%!
MY+'T`')KE5^*NB-/Y;6]X$SCS2BX^N-V<5YAKVNW>OZG)>738!XCC!XC7L!_
MCWK,KGE7E?0^BPV0T_9_OFW+RZ'TG8W]MJ5G'=6DRS0N,JRGK_A]*M]J\L^$
MVH/Y]]IS/E-HF12>ASAL?FM>IYKHIRYHW/GL;AOJU>5*]T@H-)6=K6JPZ-I4
M]_.?DC7(7NQ[`>Y-4W979S1BYR48[L@UCQ'IF@P*]]<A&;[L:C<[?0#^?2N;
M3XK:,\P0VUXB$X\PHIQ]0&S7E.IZE<ZMJ$M[=R%Y7.?91V`]`*J5RNNV]#ZS
M#Y#1]G^];<CZ5L[VWU"UCNK25987&5=3P:LUYA\)M0D;[?I[MF--LL8],\-_
M[+7I]=$)<T;GS>,P_P!7KRI7O80].E4-3U:QT>T-S?W"P1C@;NK'T`ZD_2K-
MU=0V5I+<3N$BB4L['H`*\!\3^()O$>KR7<A98%RL,1/")_B>IJ:E3D6FYT9=
ME[QDW?2*W?Z'I#_%;1EGVK;7C)G&X(O\MU=;I6KV6LVBW5C.LL1X..JGT([&
MOG&N[^%FH/!K\UEN_=3PEL?[2]#^1-9PK2<K,]7,,FI4J#J4KWC^)[)11172
M?,C>`*XKQ1XZ7P_K=O8)`)5(#7#$G**3V]\9/Y5UUU<Q6=K-<SL$BB0NY/8`
M9-?.^LZE)J^L75_)PT\A8#T7H!^``%95IN*LCU\HP,<34DYJ\4OQ9]'(ZN@8
M$$,,@CO3LUQ?PZUW^U=`%K(V;BSQ&WJ5_A/Y<?A7:=:N,N97/-Q%&5&K*G+=
M!QBBD]*Q=>\2Z=X?M_,NYP)",I$O+M]!_4\4VTE=D4Z<JDE&"NV;1SBLS4]>
MTO2`#?WT,+8SL+98_11R?RKR?7?B-JVJ%HK,_8;8\?NS^\(]V[?ABN/=VD<N
M[%F8Y+,<DFN>6(_E1[^&X?G)<U:5O);_`-?>>QW/Q2T&$XBCN[CW2,`?^/$'
M]*W?#_B2U\1V#WEM%+$B2&,B8`<@`\8)]17B/A_0Y]?UB&PARJGYI),?<0=3
M_GN17HGCMX_#?A"UTK3%\F.9C&Q'4J!ELGU)QG\:<:DK.3V%C,MP\)PP]*_/
M+SV1O7WC_P`.Z?,T+WOG2+P1"A<#\>GZU9TKQAHFLR>3:7R^:>D4@*,?IGK^
M%>#6UM<7EPD%M"\TKG"HBY)IUU97FF7`CNH);>4<@.I4_45'MY7N=<LBP]N1
M3?-\OR/I4#CI2XZ\5YU\/_&3Z@PTG47W7*C]S*QYE`Z@_P"T!W[CZ<^B<<\U
MTPDI*Z/F\3AIX:HZ<]_S`\GI67K'B'2]#B#W]VD18?*G5V^BCFN:\6^/[;2$
M>STYEN+_`*$]5B^OJ?;\Z\BN[RXO[E[BZF>:5SEG<Y-95*R6B/4R_)YXA>TJ
M>['\6>L/\5M&$N!:7K+_`'PB_P`MU=5HVO:?KUL9["<2`'#J1AE/H17SM75_
M#N_>S\76T08^5<JT;KVZ$C]0/S-1"M*^IW8W)*-.A*=*Z:5_4]THHI&(522<
M`5U'RQ7N[N"R@:>YE2*)!EG<X`%<9<_%31(IMD,-W<+_`'TC`'X;B#^E<1XY
M\4MK^J&"W;_B7V[$1@'B1N[G^GM]:Y.N:==W]T^GP.1PE34Z][OIV/H/0O$V
MG>(H6:QFRZ??B<;77ZC^HR*V^M?/?A+4I-+\3V,T9(#2B)P.Z,<'^>?PKZ#!
MR!ZXK6E/G6IY.9X%82JHQ?NO8=1116AYP4444`)7C?Q5@:/Q-!,?NRVRC\0S
M9_F*]BSU-><?%FRWV-A?*#^[D:)L>C#(S_WR?SK*LKP/3R:IR8R-^MT>55[1
M\+YQ+X2,8ZQ7#H?R#?UKQ>O4OA)=`PZE9GJK)*OOD$'^0_.N>B[31]%G<.;"
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M&JZH<W;A4AMP<!"Q`RQ[G&>.GU[<97+*]]3ZW!2H.#C0^&+M_7?U-'0=-_M;
M7;.P_AFE`?']T<M^@-?1$<211+'&H54`4`=`!TKQOX70B7Q8S'_EG;.P^N57
M^IKVFNC#K1L^:S^LY8A4^B7YGSSXITV;2O$E];S`C,K2*?[R,<@_K^>:[?P5
MXXTRUT>'2]1;[,\.560J2C@DGMT//?BNN\3>%+'Q+:A9LQSH#Y4RCE?8CN/:
MO+]2^'/B"PD/E6ZW<79X&&<>ZG!_+-2XRIRO$[*>)PN/PZHUY<LE\M>ZZ?(3
MQS:Z-_:*7VC7EO+%<9\V*)P=K^N.P/\`,>]7/A_XLMM!-U:ZC.4M9`'C(4MA
MQP1@>HQ^5<O/H6KVJ2//IEY&D8.]F@<*H'?.,8]ZI11//,D,8W.[!5&<9)X%
M9\S4N8]-86C5PWL'+F7?2YZKJ/Q7L8@5T^REN&[/(0B_U)_2N$UKQ?K.N@I=
M7.R`_P#+&+Y4_'N?Q)K>L?A9K%PP-W<6]JG?&7;\AQ^M=EH_PYT72F6:56O)
MU.0TWW0?91Q^>:TY:D]SRU6RS!ZTUS2^_P#';[CQ*BM'Q``OB/5`!@"[EP!_
MOFLZL'H?0TY\\%/N?0'@WCP?I?\`UP6M6\NX;&TFNIV"Q1(6=CV`K+\&_P#(
MGZ7_`-<%KB?B?XB+.NAV[\#$ER1^:K_7\J[.?E@F?#0PLL3C)4UW=_2YQ>M:
MG=>)]?>Y",\DS".&)1DA<_*H_P`]2:S;JVFL[F2WN$*31DJRGL17HOPO\.B5
MY-;N4RJYCMP1W_B;^GYUR?C0`>,-3`&/WN?T%<SB[<SZGU>&Q4'B'A::T@OZ
M1@U[;\,O^1.A_P"NK_SKQ*O;?AE_R)T/_75_YU5'XSFS_P#W9>J_4[&J6I7T
M&F6$][<MMBB4LQ_H/<]*NUY#\2_$IO+P:-;/^Y@;=,0?O/\`W?H/Y_2NFI/E
MC<^8P.$EBJRIK;KZ'(:MJ-SX@UJ:\D5GEG?"1KEL#HJ@50DC>*1HY$9)$)5E
M88*D=017I7PQ\.;BVN72<#,=L"/P9_Z?G7&>+`%\5ZH``/\`2&/'UKD<6ES/
MJ?8X?%0E7>&IK2"_I?(QJ]R^''_(DV?^_)_Z&:\-KW+X<?\`(DV?^_)_Z&:J
MA\9R9_\`[LO5?D=/+*D,+2R,%1`6)/0`=37@GBG79O$NO//&':('RK>,`YVY
MXX]3UKN_B;XB^RV2:-;O^]N!NG(/W4[#\3^@]ZQOAEX=^V7[ZQ<)^YMSMA!'
MWG[G\!^I]JTJMSER(\_+:<<)0EC*BUZ?UYG"WEG/87;VMU&8YD(#KW'&?ZU#
M71^.QCQKJ0']]?\`T!:YRN9JSL?3X>HZE*,WU2?WH]=^$W_(`O?^OD_^@+7H
M->??";_D`7O_`%\G_P!`6O0:[:7P(^&S/_>ZGJ-8[1D]*\'\;:__`&]X@DDB
M?=:0'RX,="!U;\3^F*]"^(WB(:5H_P!@MVQ=W@*Y'5(_XC^/3\_2O)K#2;W4
MH;J6TB,BVL?F28[#V]3U/X&L:\[OE1ZV286-.+Q533HO\_T*5>F_"W7^9-$G
M;UD@S_X\O]?SKS*K.GWLVFZA;WMNV)87#K[X[?0]*QA+E=SW<=AEB:$H/?IZ
MGT7>WUMIUH]S=S)%"@RSN<`5Y#XJ^(-YJ[/:Z:7MK(<%P</*/<]A[#\?2L7Q
M#XEO_$]ZOG96(-B*W3D#/\S[UVWA#X=+$([_`%R,/)UCM6Y"^[^I]NGK6TIR
MJ/ECL>#1P=#+Z:K8K671?U^9RGASP-JFOA9R!:V9_P"6THY8?[*]_KP*H>);
M33].U9]/T_>ZV_R232-DN_\`%TX`'3\#7NNKW@TO1KN[`&V")F`'L.!7SI([
M2R-([%G8EF)ZDFIJ04++J=N68NMC*LJLM(K1+_/N.@A>YN(X(ANDD<(H]23@
M5]%Z/81Z7I%K91#Y88PN?4]S^)R:\.\%VXN?&.F(PR!)OZ?W06_I7O\`VJ\.
MMV</$-9^TC2Z;_H>(?$;3I;'Q7-<,I\N[594..,@`,/S&?Q%:/P^\7V.CVTN
MF:B?*B>0RI-MR`2`"&Q].M>CZ]H%GXAL#:WBG@[HW7[R-ZBO*]4^&NNV4K?9
M52]BSPT;!6Q[JW]":4H2A+FB:87%X;%858;$/E:^6VSN:'Q!BT&_A75M,O[-
M[O(6:.*52TB]`V`<Y'\OI7-^%/$\GAB_FG6(S12QE7BW;<L.5.?;G\S0?!7B
M0==*F_,?XUA$$$@C!'4&LW)\W-L>IAJ%%T'0<^>/KT^7X&QKWB?4_$4^;N;$
M0.4@CX1?P[GW-=+X8^&]QJ4:WFJL]M;GE(5&)''OG[H_7Z5U7A+P5I.GVUM?
MD?:KIT61)9`,)D`_*.GX\UVW3Z5M"C?WI'B8O-E3C[#"+E2Z_P"1X'XUT&W\
M/:Z+2V+F%XED4.<D9)!&?JM<[7<_%7_D:H/^O1/_`$-ZX:L:B2DTCZ'+JDJF
M&A.;NVCT[X0??UCZ0_\`L]>H=*\O^$/W]8^D/_L]=+XZ\0G0M"?RGQ=7&8XL
M'E>.6_`?J1713:C3NSY3,J4JN82IQW=OR1Y[\0_$?]L:T;.!\VEH2@QT>3^(
M_P!!^/K7*W%C<VL,$L\+(DZ;XRP^\N<9%;'@_0#X@UZ*W=3]FB_>3G_9';ZD
M\?GZ5TGQ71([[3$10JK$P`'0#(KG:<DYL^BI5J>&JT\'3737^N[//*[GX5?\
MC5/_`->C_P#H:5PU=S\*O^1JG_Z]'_\`0THI?&C7-?\`=*GH>S4445W'P044
M4A('<4`%+5=KRW1MKSQ*WHS@&I5D1AE64CV.:5T-Q:W&R.D2&1V"JHRQ8X`'
MJ:X+6OB=8V3M%ID1O)0<&3.U!].Y_E[UW%[:QWUE-:3+NBF0HX]01@U\_P#B
M'19M`UB:QE)95^:)O[Z'H?Z?4&LJLI16AZV487#XBHXU=ULCU#P5XXE\1W$M
MI>Q117*KO7RP0KKGG@D\CCO7<=:^>?"U^=-\3Z?<YPHF5'Y_A;Y3^AKZ&!&W
M-.C-R6HLXP<,-62@K1:./^)<7F^#IW_YY2HW_CP7^M>)5]$^);(ZAX<O[5!E
MWA;9_O`9'Z@5\[5C77O7/8X?J7H2AV?YG:?"^39XM(SC?;.OUY4_TKVFO`/!
M=V+/Q?ILI;:K2^4?^!@K_,BO?QVK3#OW;'F9]"V)4NZ,[7X#<>']1@!P9+:1
M`<9ZH17SG7TU,@DA=&Y!4@_C7S3/$T%Q)"_WHV*GZ@XJ,1NCMX=EI4CZ?J1U
M]!>$9/-\(Z4V<XMT7\AC^E?/M>U^`]1A@\!V\]S*J1VYD#NYX4!B?ZU-!VD;
M\00<J,6N_P"9U\DJ0QF21PJ*,LS'``]37E/B_P"(DEV9+#1G:.#[KW(X9_9?
M0>_7Z5D^,?&T^ORM:6I:+35/"]&E([M[>@_R#PGX'NM?875UOM].'\>,-+[+
M[>]7.HYOEB<F#R^EA:?UC%_)?UN_(Y'J:*GO3";Z<VPQ!YC>6N<X7/'/TIMK
M#]IO(8,X\R14S]3BN<^GY_=YCW3P-I2Z3X6M5*XFF7SY#CG+<@?@,#\*X_XL
M:9(+JRU-$)C,9AD8?PD$LN?KEORKU&.-4A5%&`!@"J]_86^I6<MK=1K)#(,,
MK#_.*[94[PY4?!T,;*GB_K$M;MW]&>+^!O$UOX<U&8W<;&"X0*SJ,E"#P<=Q
MR:Z;QG=>&_$FD&ZM=1MA?0)NC).QG'4J0<$^WH?K6=K?PNU"WE>72)%NH#R(
MI"%D7VR>#^E<Q-X6U^V;;)I%X3_TSB+C\US7/[\5RM'T/+@\166)IU+2]?S3
M(O#NK/HFNVM\A(5'Q(!_$AX8?E^N*]3O?BAH5NN;=;BZ;ML38/S;!_2O')8I
M()7BFC>.13AD=2K*?0@]*Z+1/`VKZ]9I=V_D1VTA(#N_H<'@9/4'K2A*2TB;
MX_"82JU7KNUM-[7+VK_$K6=0#)9A+&)O^>9W/_WT>GX`5QSN\KL\C,[L<LS'
M))]Z]7TOX56,!634[I[EAUCC'EK^)ZG]*P_B;8VNG7.EV]I;I!"L;X1%P.HY
M^M$X3MS2,L'C,&JJH8:._7T]=6<%7IWP@^_K'TA_]GKS&O3OA!][6/I#_P"S
MT4?C1OG7^YR^7YH]/S7D7Q+\2_;;X:/;/^XMVS,0?O/Z?0?S^E=WXOUY/#VA
M2W"$?:9/W<"G^\>_T`Y__77D'AG19?$OB&*W<LT9)EN9,\[0>>?4GC\:VK2O
M[B/#R?#1BI8NK\,=O\S+N+"ZMK6WN9X6CBN`QB9OXP.I'YBJ]>E?%F)(4T2.
M-0J*LH`'3`\O`KS6N:<>5V/I<#B'B:"JM6O?\VCN?A3_`,C5<?\`7H__`*&E
M>RUXU\*O^1JN/^O1_P#T-*]EKKH?`?)YW_O;]$)FO&OB1XD_M35!IML^;:T8
M[R#P[]#^73\Z[OQUXD70-%*0OB\N<QQ8ZKZM^'\R*\I\*:#)XBUV*V8-Y"'S
M)WYX4'IGU/2HK2N^1'3E&'C3B\76V6WZO]#&DMYX4C>6&2-)5W1LRD!QZCU%
M1UZ-\6(8X)-(CC4*JI(``.,#;@5YS7/*/*['TN#Q'UBC&K:U[_F>@_";_D-7
MW_7`?^A"O7.F*\C^$W_(:O?^N`_]"%>B^(]9BT+1I[Z3!*+A$)^\QZ#_`#VS
M751:4+L^2S>$IXYQCN['"_$_Q'N*Z':OP,27)!_%4_K^5>=RV%U#8P7LD++;
MSLPB<]&*]?YUH:3877BCQ&D#NS23R&2:3NJYRS?Y]J[?XHVT5GI&D6T"!(8F
M9$4=@%&*PE>:<V>[0G#!2I82&K=V_N_S_`\PKKOAK_R.=O\`]<W_`/0:Y&NN
M^&O_`".=O_US?_T&HC\2]3MS#_=:GH_R/<.**3N*H:OJ<&D:7/?7#8CB7<1W
M)[`>Y.!7>W;5GY_&+DU&.[.&^*'B`0VR:+;M^\F`DG([)GA?Q(S^'O7E57[F
M>\\0:V\I4RW5W+PJ^IX`'L!@?A4%_8W&F7\UE<IMFB;:P!R/J/;O7%.7,[GW
MN`P\,+25&_O;O^OP-3PGKK:!K\%T2?(;]W./5#U/X<'\*]^5T>,2*P*D9![8
MKYEKHYO&FJ/X<M]'CD,4<:E))5;YG7LOL`./>JIU.1-,XLTRN6)G&=/1[/T[
MG<>+?B+%8&2PT<I-=#Y7G/*1GT']X_I]>E>=6.FZMXHU-O)62YG<YDED/"^[
M-V^GY5J^$O!5UXBD%Q.'@T]3R^/FD]E_QZ5[+INF6>E6:6ME`D42#A5'4^I/
M<^]6HRJN\MCDJXC#Y;'V6'7-/J_Z_(\>\2^%K+PMI,*W$[7.I7)PH7Y411U.
M.I[#GUZ<5R%=1\0=1;4/%]VN[,=OB%!Z8'/_`(\37+UC*U]#VL![1T%.J[R>
MOWGL/PNTD6NA2:@ZCS+MS@XZ(IP/UW?I1\4]/ENM`@NHE+"UDR^.RL,9_/%=
M-X9M_LGAG383C*VZ9QTR5!/ZFM&>&.XA>&5`\;J596&00>HKJ4+PY3X^>,E'
M&O$;V?X;?D>`>%=:30->BO98S)"`4D"]=I[CWKT[6M0\*^*=%:)]5LT?:6A>
M1@CQMZX;!^H[U@:[\+IQ*T^B2AXR<_9YC@K[*W0CZ_F:Y=O`_B5&*G29<CT*
MD?F#6"YH)Q:T/>J?5,;..(A4Y9+S2_!F/!/+I]_'/#(!+!(&5E.1D']175>(
M/B+J>K(8+0?8K<C#>6V7?ZMV'L/SKE]0TV\TNX$%]`T,Q4-L/7![_I78^`/"
M6GZ]'->WSR.L$H00+PK<`Y)ZX]ACI4QYG[J.[%O"Q@L357-R[==_P,+PWX3O
M_$=QB%?*M5/SW##@>P]3[5T?B_P)8:#X>6]MIIVEC=5?>00X/L!QS7JUO;PV
ML"0P1I'&@PJ(,`#V%<K\3/\`D3IO^NJ?SK5TE&#;W/"AFU;$8J"C[L;K3_,\
M2K>\%?\`(Y:9_P!=?Z&L&M[P5_R.6F?]=?Z&N>.Y]-B_]WGZ/\CZ`[9KA/B/
MXD_LS2QIMN^+J[!#$'E(^Y_'I^==G=W45E:2W,S!(HD+,Q[`5\^ZQJ5UXCUZ
M6ZVLTL\@2&,=0,X51^GXUUU9V5EU/D<HPBKUO:3^&/Y]"G%8W,UG/=Q0LUO!
MM\R0=$W'`_6J]>PZCH47A_X9W=FF#+Y0>5P/O.6&?\!["O'JY91Y79GU&!QG
MUI3DMD[+\"QI[%=2M64X(F0C\Q7TJOW1]*^:;'_C_MO^NJ_S%?2R_='TK;#[
ML\3B/XH?/]!U%%%=1\V%%%%`"5B^*=*_MGP]>6:@&1DW1Y_OCE?U%;-&<\4F
MKJQ5.;IS4X[K4^8V4JQ5@0P."#U%=3\/-3&G>+8$=L1W2F%N>YY7]0!^-6OB
M-X>.E:TU_`F+6\);@<))_$/QZ_GZ5QT4KPRI+&Q61&#*P[$=#7#K"7H?>J4,
M;A--I+[O^&9]-=36'XQMOM7A'5(]NXB!G`]U^;^E3>'-7CUO0[6^3`:1<2*/
MX7'##\ZT;F%9[2:%ONNA4_0C%=K]Z.G4^&CS4:RYMXO\F?,]%.DC:*5XW&'1
MBK#T(IM>>?HRU1>NKJ_U[4Q)*SW%S,0B*HS]%`["O6?!O@>+0E2]O0)=09>!
MU6+V'O[_`)>\7P\\-6=EI<.KOB6ZN$W*Q'$:^@]_4UWG:NJE2^TSY'-,R<F\
M/0TBM'Y^7H<!\5Y"OARU0'`>Z7/OA6KR"O9?BE;&;PLDH_Y87"L>.Q!7^9%>
M-5G6^,];(6GA=.[.[^%,VSQ)<PG_`):6Q(/N&7_$_E7L8KY[\)ZJNC^);.Z=
MML6[RY#V"L,$GZ9S^%?00/`([UM0?NV/&SZDXXGGZ-?D/HHHK8\0QO%"J?"N
MK;@,?8Y>O^X:\`L?^0A;?]=5_F*]L^(.HII_A&Z4L!)<XA49ZYZ_^.@UXYH5
MLUYKVGVZC)>=`?IN&?TS7+7UE8^JR1.&&G.6U_R1]'+]T?2@]#0.@I3T-=1\
MJ?.7B+_D9]5_Z_)O_0S6;6EXB_Y&?5?^OR;_`-#-9M>?/XC]&PW\"/HCV[2]
M6AT3X;VE_+R([8;5_O,>`/Q->2V5I>>)O$"Q;B]Q=2EI'(R%!.6;Z`5:UGQ"
M]_HNEZ5$6%O:0C?G^)_7Z`<?B:[WX8^'_LE@^KSK^^N1MAR/NQ@]?Q/Z`>M:
M*]1J/8\6RR^C4KR^.3=OOT_S.XL+*'3K"&TMUVQ1($4>PKPKQK_R.6I_]=?Z
M"O?S7@'C7_D<M3_ZZ_T%775DCBR!N6(DWV_5&#7MOPR_Y$Z'_KK)_.O$J]G^
M'=Q%:>!A/-(L<<;RN[L>``>36='XST\^5\,DNZ_4T?&7B-?#VBLZ,OVN;*0*
M?7N?H/\`"O'M`T>X\1ZY%:*SD.2\\IY*KW8GU_J:D\4:_+XCUN2Y^;R5/EP1
M^B]N/4]:]7\"^&AH.C+).@%[<`/+D<J.R?A_.K_BS\CE5LKP=W_$E_7X?F=)
M:6L5G:Q6\"!(HE"JH[`5X'XN_P"1NU3_`*[M7T)7SWXN_P"1NU3_`*[M3Q&R
M.?(&WB)-]OU,6O9?!=_!I?PXCO;AML4/FNQ]?G/'U/2O&JW;K7R_A&QT*'<J
MQN\LYQPQ+$J!],Y_+TK&$N5W/<S'"O%0A36W,K^EF5II+SQ/XB+8W7-Y-A5[
M+G@#Z`?H*]YT;2X='TFWT^`?)"@7.,%CW8^Y.37`?"W0/];KDZ^L5OG_`,>;
M^GYUZA711CIS,^>SG$J518>G\,/S_P"`>">//^1VU/\`WU_]`6N<KH_'G_([
M:G_OK_Z`M<Y7-+=GU6"_W>G_`(5^1Z[\)O\`D`WO_7R?_0%KM[Z]@TZRGN[A
MML42EG8^@KB/A-_R`+W_`*^3_P"@+6)\2O$WVNZ_L6U?,,+;IR#]Y^R_0?S^
ME=49\M-,^4JX26)S&=-;7U]#D-9U2Z\0ZY+=LK-),X6*,<[5Z*H'^>:]H\)^
M'H]`T*.T=`;B7YYVZY8CI]!T_P#UUQ'PS\-&XN/[<N8_W,1*VX/\3]V_#H/?
MZ5Z7JFHV^DZ?/?7+A8H5W$^OH![D\5-*/VY&N;XGFE'"4-EV[]%\OS/$/&6A
M?V#XAGA1,6TO[R'C@*?X?P.1],5S]:6N:S<Z]JLM[<GEN(T!XC3LHK-KFE:^
MA]/AHU(T8JK\5M3T+X5V5A<7UW<2QA[RWP8]W(53G)`]<CK[UZWVKP_X<7AM
M?&,"9.VXC>(_EN'ZJ*]PSC-=E#X3Y'/(2CBW=[I6.:^($IB\$ZBR]2$7\"Z@
M_P`Z\'KW[QO`+GP;J<>,XBW_`/?)#?TKP&L:_P`1ZW#S7L)+^]^B.D\`N(_&
MVF,>A9Q^<;#^M>]5\U:=>/I^I6UXN=T,JR`#O@YQ7T=:W,5Y:17$+AXY4#HP
M[@C(J\.]&CBXAI-58U.C5ON_X<L4445T'SPT@8/TKYHO&#WL[*05,C$$=QFO
MH3Q!J2:3H-Y>NV/*C)7G&6/"C\R*^=E4LP5022<`#O7+B'JCZ;AZ#4:D^FB_
M,^AO"_\`R*VE?]><7_H`K7':JFGP"STZUM@`!%$J8'08`%6QVKJZ'S=1IS;7
M<\:^*O\`R-4'_7HG_H;UPU=S\5?^1J@_Z]$_]#>N&KAJ_&S[O*O]TI^AZ;\(
M3M.LL>PA_P#:E<IXUU[^WO$,LL;[K:']W!Z$#JWXGGZ8J+1=?;1M$U>VAW"X
MO1'&CC^%1OW'ZX;`^OM5SP'H)UOQ"CR+FVM<2R^A.?E7\3^@-/F<HJ".9T8T
M,16QE796M]R_70])\!>'SH>A*TR;;NYQ)+GJ/[J_@/U)KD_BW_R$M-_ZY/\`
MS%>KUY1\7/\`D):;_P!<G_F*VJKEIV1XN5UI5LP52>[O^1YS7<_"K_D:I_\`
MKT?_`-#2N&KN?A5_R-4__7H__H:5A2^-'TF:_P"Z3]#V7%)^M13SQVT#S3,J
M1HI9F8X``]37#V7Q+M;WQ%%IT5E(;>601QSAN22<`[<<#\>G-=DIJ.Y\/2PU
M6JI2A&Z6YUVL:G#HVE7&H3Y*0INVCJQZ`#ZD@5X9K7BO5M<N7>>ZD2$D[8(V
M*HH],#K]37K'Q"MI+GP9>>4"3&4D8#NH89_(<_A7AE<]>3O8^BR##TI4Y59*
M\KV]!54LP5022<`#O5Y;75]/7SUM[ZU&,^8$=./K6OX#N+2V\6VS7A15(98V
M?HKD<?3T_&O==BL.0"*FG2YU>YTYEF;PE14^2Z:/$]%^(NM:6ZI=2?;K<=5E
M^_CV;K^>:U/&^HZ?XGT"VU>P?][;N$E1N'16]1]0,'W-=!XL^']IJL+W>F1K
M;WP&=HX27V(['W_.O(9HI[2:6WF5XI%.R1&X/!Z$?443YX^ZQ82&%Q<U7H+E
MG'=?\#]2-6*L&4D$'(([5]*VDWVBTAEP/GC5OS&:^::]_M-<TW3M'LA=WUO"
M?L\?RR2`'[H[=:=!I-W,>((.7L^57>OZ&Z>1@]*^?_%VDG1O$MW;!<1,_FQ?
M[C<C\N1^%>K3_$+PU`Q4:@78?W(7(_/&*XKQSKN@>(K*&>SN6^W0-@*\3#>A
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M3X%?56CU+4T*V(^:.,\&7W]E_G7JUV%M],F6)0JI"VT*.``.,"K2H$4*H``X
MP.U-N8A+:RQY^^A7\QBNV--1C9;GQ&*QM3%55.>RV78^9JLZ=(L6IVDCG"),
MC,3V`85`Z-&[(XPRG!![&FUQ'WC7-"Q].@9`/M0*QO"VK#6/#UG=Y!<H%D'H
MXX;]:VJ]!.ZN?F]2#A-QENM!:0@8Z4M12RI%"\CL%5`6)/8#J:9*/`_&O_(X
MZG_UU_H*]1^&I)\&6P(Z22`?]]&O'-7O3J6KWE[VFF>0#T!/`_+%>V^!+4VO
M@S34;JZ&7_OIBP_0BN6EK,^IS=<F!IPEOI^".EKR?XN?\A+3?^N3_P`Q7K!K
MR?XN?\A+3?\`KD_\Q6E?X#R\E_WR/S_(\YKT[X0\-K!]H?\`V>O,:W=$\0/H
MNCZM!#N%S>A(T<=%4;]Q^N&X^OM7-3ERRNSZK,J$J^&E3AN[?FBUXZU[^W?$
M#^6^;6VS%%Z'^\WXG]`*]'\`>'SHNA+/,F+N[Q))D<JO\*_ES]37G/@3P^=<
MU]&E3=:6N)9<CAC_``K^)_0&O=<8Z5O2CS/G9X&;5XT:<<'2V6_]?B>8?%_[
M^C_2;_V2O,:].^+_`-_1_I-_[)7F-95OB9[.2_[E'Y_FSN?A5_R-5Q_UYO\`
M^AI7KUU=0V5K+<W#A(8U+,QZ`"O(?A4,^*KC_KT?_P!#2M#XF>)S+)_8=J_R
MH0URP[GJ%_#J?PK6$^6G<\?'866)S'V:\K^2..\1:U/XCUV6Z(;:QV01=2J]
MA]3U^IKU[P7X=3P_HB+(H^USXDG/OV7\/YYKB?AKX9^VWIUFZ3,$#8A5A]Y_
M[WT'\_I7KN?2BC"_OLC.,5&*6$I?#'?_`"/+/B[_`,?.E?[DO\UKS6O2OB]_
MQ\Z5_N2_S6O-:QJ_&SW<H_W.'S_,]!^$_P#R&K[_`*X#_P!"%4_B-X@&J:S]
M@@;-K9DJ<'AI/XC^'3\ZR/#?B`^'UU&1%/GSV_EPL.@;(Y/T&3^%)X4T1_$7
MB&&WD#-"#YL[?[(Z\^I/'XTU)N/(C"6'C3Q<\75VBM/N_I'HWPUT#^SM'.HS
MIBXO`"N>JQ]OSZ_E5+XN?\>6F?\`75_Y"O1458T"J`%48`%><_%S_CQTS_KJ
M_P#(5M4CRT['AX&O*OF,:DNK?Y,\JKKOAK_R.=O_`-<W_P#0:Y&NN^&O_(YV
M_P#US?\`]!KFC\2]3ZG,/]UJ>C_(]N]:\?\`B3XD_M#4?[*M7S;VQS*5/#R>
MG_`?YDUV_CCQ*N@:.5A8?;;@%(1W7U;\/YXKR3PYHD_B/7(K52VPG?/+UVIW
M/U/3ZFNBM._N(^=R?"QBGBZVD5M_F=I\,?#62==N5]4M@P_`O_,#\:F^*>A!
M[>'6XD^:/$4^.ZD_*?P/'XBO1;6VBL[6.WA0)#&H5%'0`=*\A^(7BMM4O6TJ
MTD(LX&Q(0>)7']!_/GTHG&,*=F&$KU\7C_:PV7X+M_74X:M/P[!9W7B&RM[\
M$VTL@1AG&2>%&?3.*S*='(T4B2(VUT(92.Q%<R/JZT7*FXIVN?2T$,=O`D4*
M+'&BA551@`#L!4IZ&J]A<K=V$%P,8EC5QCW&:LGI7H+;0_-I74FGN?-VM.9-
M=U!SU:ZE;GW8U2K4\20-;>)M3B;M<R$?0L2/T(K+K@>Y^C4&G2BUV1]&Z'*L
MV@Z?(ARK6Z$'_@(K1[UQWPWU5=0\+QVY8&6T)B8=\=5/Y<?A78]Z[8.\4?G^
M*I.E6G!]&Q:**#P*LP/%?BD,>+$_Z]D_]":NE^$O_('U#_KX'_H-</XXU$:G
MXMO94(,<3"%".^T8/ZYKT#X56S0^&YYV_P"6]PQ7Z``?SS7+#6K<^JQD73RJ
M,9;Z?YG>5QWQ-_Y$Z;_KK'_.NQKCOB;_`,B=-_UUC_G6]7X&>!@/]YAZH\2K
M>\%?\CGIG_77^AK!K2T#4$TG7;2^E#%(7W,J]2,'I7#'<^[Q,7*C.*W:?Y'H
M7Q2U_P`JWBT6!CNEQ+,0>B@_*OXD9_`>M9?PPT#[7J$FL3)F&V.R+/>0CD_@
M#^H]*Y&ZN+OQ)K[2E=]S=S`*H[9X`^@&/RKWK1-+BT71[:PA'RQ)@G^\W4G\
M3FNB"YY\S/GL9)8#!1P\?BEO^O\`D4/''_(FZG_US'\Q7@5>^^./^1-U/_KF
M/YBO`JBO\?R.GA[^!+U_1$]C_P`?]M_UU7^8KZ67[H^E?--C_P`?]M_UU7^8
MKZ67[H^E5A]V<O$7Q4_G^@@_(4ZN*\3_`!`M?#]X+.WMQ=W"\R*'VA!Z9P>?
M:NHTK4(]5TJVOHT9$GC#A6ZC/:NA33=D>%/#5:<(U)QM%[%ZBBBJ,`HHHH`S
M=8TFWUO3)K&Y&8Y%QD=5/8CW%>!:UH]SH>IRV-TN'0Y5P.'7LPKZ.KGO%7AB
MV\2Z?Y3@)<QY,,V.5/H?8UC5I\VJW/6RK,?JL^6?P/\`#S/-OAYXE&D:H;"Z
M?;:73#!)XCDZ`_0]#^%>M:KJEMI&GS7MTX6&-23SR3V`]S7SWJ&GW6EWTMG=
MQ&.:(X(/?W'J#5S4O$>I:MIUI974V^&V'R^KGL6/<@<5E"JXIIGLXS*H8JM&
MM3>CW_S1GWEQ]KOI[GRQ'YTK2;`<A<DG'ZU#4DUO-`L331L@EC\R/</O+DC/
MTR#4=8'N0MRVCL>[?#Z0R^"=/+$$J'7CV=@/TQ745R/PU;=X+MAC[LD@_P#'
MB?ZUUQKOI_"C\]QJMB:B\W^9E^(-,&L:#>6/&Z6,[,]F'*G\P*^=W1HY&1U*
MNI(92.0?2OILC(Q7D7Q'\*O97C:S:KFVG;]^H'W'/?Z'^?UK*O"_O'KY%BU2
MFZ,G\6WK_P`$\_KU/P-X\@-K%I>KSB.2,!(IY#\KKV#'L1TR>M>645SQDXNZ
M/HL9@J>*I\E3Y/L?322)(H*,"#T(.0:J:CJUCI-JUS?7,<,:CJQY/L!U)]A7
MSU;ZC?6J;+>\N84_NQRLH_0U#/<37,GF3S22N?XI&+'\S6SQ#ML>''AU\WO5
M-/34W?%_B>3Q+J8D0,EI$"L,;=?=C[G^@K;^%VC-=ZV^IR)^YM%*H3WD88_0
M9_,5R.DZ3=ZUJ$=G9Q[Y'Y)/W4'=B>PKWS0=&M]!TF&PMP2J#+.>KL>I-*E%
MSES,WS/$4\)AOJU+=JWHNOWFK0>AHH/0UUGR1\Y>(O\`D9]5_P"OR;_T,UFU
MI>(O^1GU7_K\F_\`0S6;7GS^(_1L-_`CZ(U_#6BOK^O6]B`=A.^5A_"@ZG^G
MU(KZ"AA2"!(HU"HBA5`Z`#@"N(^&>A_V?HC:C,F)[PY7VC'W?SY/Y5W8KKHP
MM&_<^0SG%^WK\L?ACI\^HIZ5\_\`C7_D<M3_`.NO]!7T`>E>`>-@1XRU/(Q^
M\_\`9148C9&_#_\`O$O3]48%;K^(I5\)0:'`'C7S&>=\_?!.0H]NY_"L*M+0
M=%GU_5X;"#C<=TC]D0=6_P`]\5S*_0^HQ$:7+SU=HZ_<=7\./#!U&]_M>Z3-
MM;M^Y5AP\GK]!_/Z5[".E4M.T^WTRQAL[9=L42A5'^-7:[J<.16/A<=BY8JL
MYO;IZ!ZU\]^+O^1NU3_KNU?0E?/?B[_D;M4_Z[M65?9'I\/?QY>GZF+5S2]/
MFU;4[:QMQ^\G<*#Z#N?P&3^%4Z]0^%FA;4GUJ9>6S%!GT'WF_/C\#7/"/,['
MT6/Q2PU"4^O3U/0]/L8=-L8+.W7;%"@11["K>.*!1TKT$K'Y^VY.[W/!/'G_
M`".VI_[Z_P#H"USE=)X^1E\;ZEN&,LA'T*+7-UY\MV?HF"_W:G_A7Y'7>'_%
MB^'O"M[;VY)U">8F/CB-=H&X_K@5CZ!HMSXBUJ.TC+8<[Y9#SM7NQ]_ZFLR*
M*2>9(HD9Y'8*JJ,DD]`*]T\&^&4\.:2JR!3>S8:9QZ]E'L/\:TA%S:71'G8^
MM3P$)2A\<_Z^Y&]96D-A90VENH2*)`B*.P%>9?%766>[MM'C)"1J)I2.['(4
M?@,G\17JHQ7AOQ&21/&UXSYVND;)D]M@'\P:VKZ0LCP\E@JF+YI[I-_,T?AW
MX8BU8W5_>(&A16AC4C(+,OS'\`?UKAYX6M[B6%\;HW*''J#BO4O`?B32=/\`
M"+Q75S'#+;,[NC,`S@G(*COUQQWKRZZG-S=S7!7:979R!VR<USR2458^AP4Z
MT\56YU[JLE^.WYF[X%C:3QIIH7/#LQQZ!2:]['2O*OA5HKM<W&L2J1&JF*'/
M\1/+'\.!^)]*]6/6NB@K1/GL\K*IBK+[*L07$"W%O)"XRDBE2/8\5\YZG82Z
M9J=S8S?ZR"0H3ZXZ'\1S7TGWKS?XD>%7NT_MFRCW2QC;.BCED'1O<CO[?2E6
MA=70\DQ:H5G";TE^9Y37>>!O&RZ2JZ9J3$6A/[J4\^7GL?\`9S^7\N#HKFC)
MQ=T?68K"T\53=.:T/I>"XAN85E@E26-AE61@01[$4ES>6]G`TUU-'%$HRSNP
M`%?.-O>W=IG[-<SP9Z^5(5S^5-N+RZNV#7-S-,1T,KEL?G6_UAVV/G_]77S?
M'IZ:_F=;XZ\8KK\RV5B6%A$VXL1@R-ZX]!VK.\$:0VK^*+52F8(&\Z4]L+T'
MXG`K"MK::[N8[>WB:6:1MJ(HR2:]R\&>&4\.Z3LEVM>38:9QV]%'L/YYJ()U
M)79V8VK2R_">QI;O1=_-G4`<4445V'QQXS\5?^1J@_Z]$_\`0WKAJ[GXK?\`
M(U0?]>B?^AO7#5PU?C9][E7^Z4_0*]W\#Z$="\/1)(F+F?\`>S9Z@GHOX#`^
MN:\Q\`Z%_;7B*-Y$S;6F)9,]"?X5_$\_0&O=16M"'VCQ\_Q=VL/'U?Z!7DWQ
M;_Y".F_]<G_F*]9KR[XN6S!M,N@/D_>1L?0\$?U_*M*WP'G9,TL9&_G^1YE7
M8?#:_M=/\232W=Q%!&;5U#RN%&=R'&3[`UQ]%<D7RNY]EB:"Q%*5)NUSNO'7
MC8ZQ*VG:;(18H?WD@R/-/_Q(_6K/PQ\.FYNVUJX3]U"2D`/\3]V_`<?4^U<9
MH>CW&NZM#8VX^9SEWQPBCJQ_SZ5]!:;8P:9I\%E;KMBA0*!_4^YZUM3BYRYF
M>!F52G@L.L+1W>_IW^9/)&DD91U#*PP01D$>E>4>)_AM=6TSW6C#SK=B6,!/
MSI[#U'Z_6O6\`BE[5O.FI[GA83&U<++FIO?==&?,T]M/;2F*XADAD'5)%*D?
M@:W--\;Z_I<:Q0WK2Q*,!)P'`^A//ZU[I=6-K>Q>7<VT,R?W9(PP_(UC7'@;
MPW<??TF$?]<RR?\`H)%8^PDMF>Y_;E"M'EQ%*_W/\SS@_%+Q`?X++_OTW_Q5
M<WK.LW&N7OVRZBA28C:S1)MW8Z9YYKV'_A7'A@G/V%_IY[_XT^Y\&Z!9Z7=?
M9M+M]XA?:T@+D':<'+9I2IU&M6%+,L!2FG1IM/Y+]3PJNJL/AYXAOT#^1%;H
M1E6FD`R/HN37,P1-<3QPIC?(P1<^I.*^E(TV1J@Z*`*FE34WJ=N;YA4PJBJ=
MKN^_R/,[;X12G!NM74>JQ09_4G^E3O\`".`QD1ZM(K=BT((_+(KTNBM_90['
MSSS?&-WY_P`%_D>$>)_!-[X:B2<RBYMW.TR*A78>P(YZUBZ/JD^C:I!?VY^>
M-LE<X##NI^HKZ)O+2"^M9;:YC62&1=KHPX(KPSQ;X4N?#5Z3\TEE(W[J7'3_
M`&6]_P"?\L:E/D=UL>YEN9+%Q=#$?%^:/;-+U.WU;3H+VV<-%(N>O(/<'W!X
MKQ[XA:W:ZQX@"6@W1VJF(RYX<YR<>PZ5CZ;XCU+2M-O-/MIML-R,-ZH>Y4]B
M1Q6?':SS6\UQ'$S0P;?,<=%R<#/U-3.KS)(O`Y4L+7E5F]-E\^_Y$->B?"5\
M:IJ$?/S1*WMP?_KUYW7=_"EV'B>Y3/RFT8D>X=/\34TOC1UYLKX.?I^I[)01
MD445WGP9X#XVTDZ3XINT"XBF;SH_HW)_(Y'X5SU>X>._#!U_2!+;J#?6^6C[
M;QW7_#W^M>(NCQR-'(K*ZDAE88(([&N&I#ED?=93BU7PZ5_>6C_S^9T_@OQ:
MWAJ]:.<,]A,?WBKU1O[P'\__`*U>T6.IV6I6XGM+F.:(_P`2-G%?-U2P7,]K
M)YEO-)"_]Z-RI_,4X57#0RQ^3T\3+VD7RR_,^E))8XD+R,JJHSN)X%>7>._'
M$-U;R:3I,H='XGG4_*1_=4]\]S^%<!<:A?7:A;B\N)U':65F'ZFJZJ68*H))
M.`!WJIUG)61A@\CA0FJE67,UMV+ND:;+J^K6MA"#OG<+G^Z.Y_`9-?15O`MM
M;Q01C:D:A%'H`,"N*^'_`(2;1K<ZC>I_IDZX5".8D]/J>_\`^NN[-:T865V>
M3G.-CB*RC!^['\^H5Y/\7/\`D):;_P!<G_F*]8KR?XN?\A+3?^N3_P`Q17^`
MC)?]]C\_R/.:55+,%4$L3@`=325V'PZT(:KKXNIDS!9@2'(X+_PC^9_"N2*;
M=D?8XFO&A2E5ELCTOP;H']@:%%`ZC[1)^\F/^T>WX#`KH^]%%>A%)*R/SRK4
ME5FYRW9Y?\7_`+^C_2;_`-DKS&O3_B\C$:1(!\J^:"?<[,?R->85QUOC9]MD
MO^YQ^?YLVO#>O-X>N[J[B3=,]LT4>>@8LI!/L,&H='TNZ\2:ZELC%I9W+S2G
MG:,Y9C_GJ:S%4LP502Q.`!U->X>!?#*Z!I"RS)_IUR`TN>J#LGX=_>B$7-VZ
M$YCB*>#C*K%>_+1?UV1T6GV,&FV,-G;KLAB0(H]JM]J!17:E8^);<G=[GE?Q
M=_X^=*_W)?YK7FM>E?%[_CYTK_<E_FM>:UPU?C9]SD_^YP^?YA7MGPZT(Z3H
M"W,J8N;S$C9'(7^$?ES^->9>#]#.O>(8+=US;Q_O)CVVCM^)P*]]50H``P!T
M`K2A#7F/-S_%VMAX]=7^@ZO-OBY_QY:9_P!=7_D*])KSGXMIG3=.DYXF9?S7
M_P"M6U7X&>/E/^^0^?Y,\GKH/!FJVVC>(H[Z[?9$D;]LDG:<`?6N?HKB3L[G
MW-6DJM-TY;-6-37-9N_$>LO=S*2SG9%$O.Q>RCU_J37L/@GPTOA[1U\T#[9/
MAYV]/1?P_GFN2^&_A,S2KKE['B)#_HR'^(]W^@[>_/85ZKQGI731A]MGRF;X
MR-EA:/PQW_R^1SOC;6&T7PS<3Q-MGEQ%$<X(9NX]P,G\*\8\/:.^N:W;V"DA
M';+L/X4'+'\OUKTGXLHYT*R<?<6YP?J5./ZUR/PYU2STOQ&YO'2-9H3$DKG`
M5L@X)Z#..M15UJ69U9:G1R^=6FKR=_P_RW(_B%ID&E>)1%;QK'');QN$4<#&
M4_\`9:Y2NL^(>L0:OXB7[+*)(((1&&4Y4MDDD'OU`_"LOPSHKZ]KUO9A28MV
M^9O[J#K_`(?C6<DN9I'JX2HZ>"C.MI9:GN7A^!H/#VG0O]^.VB5L>H0"M2FJ
MH50`,`>E/KN2LCX.;O)ON>-?%#26M/$*7ZK^ZO$&2!_&O!_3;^M<+7T%XIT&
M/Q#HLMFQ"R_?A<C[KCI^!Z'ZUX'>6<^GW<EK=1F.:-MK*>U<=6'+*Y]GDV,5
M6BJ;?O1T^73_`"-3PSXAG\.:JMS'EXG&R6/.-Z_XCM7M^CZ]I^N6PFLKA7_O
M+T9?8CM7SM3XI9(9!)%(T;CHRG!'XT0J.!IF&4PQ3YT[2[_YGTQO4#)(K@_&
M?CN#3[:2PTR=9;QP59T.5B'?GNWMVKRN75-0GC,<U]=2H>JO,S#\B:J54J[:
MLCBPN0QIS4ZLN:W3_,='&\TJQHI>1V"J!U)-?0_A[2QHN@VE@,;HHP'([L>6
M/YDUY_\`#CPB[S)K=]&51?\`CUC88)/]\CT]/S]*]4[5="%O>9Q9YC8U9JC!
MZ1W]?^`+7'?$W_D3IO\`KK'_`#KL:X[XF?\`(FS?]=$_G6E7X&>9@/\`>8>J
M/$J**FM;:6]NXK:!-\LKA$'J2:X3]!E)1CS,[_X7:!YUU)K4Z?)#F*#(ZL1\
MS?@#C\3Z5ZS6;HNEPZ-I-M80_=B0`G'WCW/XG)K2KOIPY8V/S['8EXFO*ITZ
M>ASOCC_D3=3_`.N8_F*\#KZ!\80-<>$M3C0$MY!8`=\<_P!*^?JYJ_Q'T7#S
M7L9+S_1$UHZQWD#N<*LBDGT&:]<\6>/+33=/^SZ5=1SWLH^5D(98AZD],^@_
M.O':55+,%4$DG``[UG&;BG;J>EB\#3Q-2%2I]GIW]36\/Z/<>(]>BM=SG>QD
MGD)R57/S$GU_J:^@+>VBM;:*WA4)%$H1%'0`#`%<OX#\-?V#I/FSIB^N</+G
MJ@[+_C[GVKK\\UU48<JNSY7-L;]8K<L/ACM_F+1116QY04444`%)15>\NXK&
MSFN9F"10H7=CV`&:!I-NR/.?BO/I_EVD)C5M0)W*P."B>_KD]/H:Y+P;X;?Q
M'K*HX(LX,/.P[CLH]S_+-9VK:C<^(M=ENV5FEN)`L<8.<#HJC]*]N\*Z"GA_
M0X;08,Q&^9Q_$YZ_@.@^E<D5[2=^A]57JO+L#&DG[[_#O]QPOQ6LE@ETF2-`
MJ"-XP%'"A=N!^OZ5YS7KGQ9BW:%938SLN=N?0%6_PKR.HJJTV=N33Y\(K]+_
M`)GMOPR_Y$Z'_KK)_.NQKCOAF,>#HN.LLG\Z[&NJE\"/DL?_`+S/U8M1RQ)-
M&T<B*R,,,K#((J2BM#D1YAX@^%WF2M<:),J!CDV\I.!_NM_0_G7$7?A+7[%B
ML^DW7'>*/S!^:Y%?0M)CVK&5"+V/9P^=XFC'E=I+SW^\^=8?#FM7#A(M*O23
MW,+`#ZDC`KI=(^&.KWC*^H-'90]P2'D/T`X'XG\*]E`]J,'UI*@NK+JY]B)*
MT$H_B9&AZ!I_A^T$%E%M)^_(>6<^I/\`D5L=>**.U;))*R/%G.4Y.4W=L6@]
M***9)XOXV\':E;ZW<WUG:27-K<.9`85+,C'E@0.>N3FJWACP+J.K7\3WUK+;
M6*G,C2J49QZ*#SSZU[?[<48[<5C[!7N>Q'.Z\:/LDEM:_P#74;'&D4:QHH5%
M`"J!@`#M4E%%;'CB&O,_'_@R\O[[^U=-B\V1D"S1+C<2.`P]>./P%>F&C&14
MS@IJS.C"XFIAJGM('SO:^&-<O+@0QZ5=*V<$R1%%7ZDX`KV'P?X5B\-Z>0VV
M2\EP99`/_'1[#]:Z4@`\<4ZIA147<Z\9FM;%1Y):+\Q:***T/,$KQWQYX3U%
M==GU"SM)+BWN"&/DJ69&QSD#GWS[U[#G%(>>>U3."FK,ZL'C)X2I[2"OT/"-
M"\$:OJ]VBR6LUI;9_>2S(5P/8'DFO;K"R@TVRAL[9-L4*!%'L*M`#VI12A34
M#3&YA5QC7/HET%HHHJSA/.?B#X/NM6F35-.3S9E0))$#@L!T(]_:O.X/#6MW
M$_DQZ3>;\X^:%E`^I/`KZ(`]J0`#I64J*D[GKX7.:^'I*DDG;8X;P9X#71'%
M_J)26]Q\J#E8OH>Y]Z[NBBKC%15D>=B,14Q%1U*CNP'2N*\=>#F\0Q175GL6
M]A&T!N!(O7;GL1SCZFNU^M%$HJ2LQ4*\Z%15*;U1\ZS>&];@F,3Z3>[QV6%F
M!^A`P:Z/P_\`#?4K^=)=40VEJ#EE)&]_8#M]3^5>S8'H*#[8K)4%?5GK5<^Q
M$X<J23[D%G9P6%K';6\:QQ1KM1%Z`58HI:WV/$;;=V%(0",&EHH`\]\2?#6V
MU&1KK276UG;EHV'[MC[8^[_+VKS^]\&>(;!CYFES.`?O0C>#[_+FOH$<4AYK
M&5&+U6AZV&SG$T8\OQ+SW^\^<TT#6)&"KI5\Q/\`TP?_``K=TWX<Z_?N#-"M
MG%W>5AG\%&3^>*]O`'I2]*E8==6;U,_Q$E:*2_$YKPWX.T[PXN^)?.NB,-/(
M/F^@]!72T48K=1459'BU:LZLG.;NQ:***9!YY\2/#%YJPM]0L(3-)"I1XU&6
M*YR"!WP<\>]>=V7A77+^<11Z7=*2<%I(S&J_4MBOH7%&`!QQ64J*D[W/6PN<
M5L/15)).VQ@>%?#<7AO25MU823N=\TF/O-[>P[?_`%ZZ#VHH[5HDDK(\RI4E
M4FYS=VPK'\0Z'!X@TF6QF.UCRCXR48=#6QU%'3J:&DU9BA.4)*<79H\`U/P9
MKVES,KZ?+,@.!)`ID5AZ\<C\0*;IO@[7=4F$<6G31+WDN$,:C\3U_#-?0&.*
M,<5C]77<]O\`U@Q'+;E5^YSWA;PM:^&;+8G[RYD`,LQ'+'T'H!71=Z.:*V24
M59'BU:LZLW.;NV+1113("BBB@!*AN(O.MY(R>'0KGZC%3T4#3L[GBOA'PCJ1
M\51-?6<L4%G)YCLZ$*S+]T*?XN<'CM7M&*,=Z6IA!01U8S&3Q<U*>EE86BBB
MJ.0;6'XIN;&W\.W;ZC$LMOLP8V_B/8#WSCGMUK<QS7COQ-U\WVJKI4#_`+BU
MY?'\3D?T''XFHJ2Y8G=EV%EB,1&*V6K.+MK:6^NXK:W0M+,X1$'<FO6M2\,0
M:1\-;VPCPTBQ":67'+NI#$_3C`]JSOAAX="H^N7,?S-F.W!'0=&;\>GX'UKT
M#5[<7>C7UN1D2P.F/JI%8TZ?NML]3,\P<L1&E!Z1:;]?^`?-]=M\+#_Q5K_]
M>K_^A+7$UV_PL&?%DA]+5R?^^D']:QI_$CW,R_W.?H>T4445WGP(E<=XH\!V
M6O,US"?LUZ?^6JKD/_O#^O7ZUV-%3**DK,UHUZE&?/3=F>"ZAX#\0V#-_H+7
M"#H]N=^?PZ_I66-!UDMM&DWV>F/L[Y_E7T=BC:/0?E6+PZ[GM0X@KI6E%,\(
MT_P!XAOW&ZS^S1GJ\[;<?AU_2O1?#/@&PT(I=3$W5Z.DC#"I_NKZ^YY^E=D*
M*N-&,=3BQ6;8G$+E;LO(4#`HHHK4\T2N$^(GAFZUNUMKJPC\V>WW!H@0"ZG'
M3W!'3W-=W14RBI*S-L/7G0JJK#='SS:>%M<O+D6\>EW*OG!:6(HJ_4GBO:?"
M^@Q>'=(2S0AI"=\KXQO<]?P[#Z5N;0.PH`J84E!W.O&YI5Q<5&6B'4445H><
M<UXQ\/GQ'HK6T9"7$;>9$S=-PXP?8@UXS-X:UNWG,,FE7F_./EB9@?H1D'\*
M^BJ3:/09K.=)2=ST\%FM;"0<(JZ/,O!'@.>VNUU/5XPCQG,,!.2&_O-_05Z=
MB@4GKS50@H*R.3%8JIB:GM*G_##J***HYSB?B'X<NM<TV"6RC\RXM6)"`\LI
MQG'OP*\LM_#&N74XACTF[#YP=\10#ZDX`KZ'[T8&>*RG14G<]7!YO5PM+V44
MFNAS'@WPJOAK3F$C"2\F(:5QT&.BCV'/YUU'>BCM6D8J*LCSJU6=6;J3=VPK
M`\6:$/$.ARV8(64$/$QZ!QTS[')'XUOT4-)JS)ISE3FIQW1\\7?A?7+*Y,$N
ME73-G`,<1=6^A&0:Z7PQ\.;V]G2XUA#;6JD'R2?GD]O]D?K_`#KV`C/I2XYK
M)4$GJ>Q5SW$3AR))/O\`Y#8HDBC6.-0J*`JJ!@`#M4E%%;'BF7K>D6^N:5-8
M7&0LHX8=58<@CZ&O$]5\&:WI5RT;6,T\8.%E@0NK#UXY'XU[_32`>PK*=)3U
M/0P695<)=1U3Z'@NE>"->U650ME);Q'K+<`H`/7!Y/X"O7/#'A:S\,V7E0DR
M7#X,LS#!<^WH/:M_&,=*.].%)1U*QF:5\4N1Z1[(=1116AYHG>N<\2^$K#Q)
M$#,OE72#"3H/F'L?4>U='12<4U9ETJLZ4U.F[-'ANI_#K7["0^3;K>1=GA89
M_%3S_.L-M!UA&VMI-\&]#;O_`(5]'=:0@>E8/#KHSVZ>?UXJTDG^!X%8^"?$
M-^ZB/3I(E/5I_P!V!]0>?TKO?#OPRM+!TNM6D%W,O(A`_=J??/WOT'M7H':E
M%5&C%;ZG-B<YQ-9<OPKR_P`P4!1@#`%+116QY0E8WB?2#K?A^[L5($DBY0GH
M&!!'ZBMCI1GG%)JZLRJ<W3FIQW6I\[R^&=<AN?(?2KS?G&%A+`_0C@CWKT+P
M)X)N-,N1JNIH$N,$10Y!\O/5C[XXQ_D>BD`]:7'M6<:*3N>KB<YKUZ;IV2ON
M.HHHK4\@C9`Z[6&01@@]Z\<\3?#S4+*\EN-)B-S9N2RQK]^/VQW'H17LO0=:
M#4SIJ:U.O!XZKA)N5/KNCYUB\.ZU/,(DTJ]W^AA88^I(XKT3P=\/CI\R:EK`
M1IUYBMQR(SZL>A/MT'\O10O?C-!%9QH).YVXK.J]>'(ERI[VW'CI1116QXX4
M444`%%%%`"8KSGXIZV;>QAT>%\/<?O)L?W`>!^)_]!KT1F"@L3@"OGGQ-JIU
MKQ#>7V28V?;%[(.%_09_&L:TK1MW/8R7#>VQ'.]HZ_/H=)\,M$%]K3ZE*F8;
M0?+GH7/3\AD_E7LG>N<\%:2-'\+VD3+MEE7SI?7<W.#]!@?A718YJJ4>6)S9
MEB?K&(E+HM%\CC_B9'O\'3-C[DL;?KC^M>)5[C\2/^1*N_\`?C_]#%>'5SU_
MC/HL@?\`LS]7^2/=OA]`8/!5@&ZOO?\`-V(_3%=.*S=`M38^'["V/WHH$5N,
M<X&?UK3KJ@K11\IB9\]:4^[?YBT4451B%%%%`!1110`4444`%%%%`!1110`4
M444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!11
M10`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%
M`!1110`4444`%%%%`!1110!D>(]630]"NK]L%HTQ&I_B<\*/SKP?3;*?7M=@
MM0Y:6ZE^=SR>>6;\LFNX^*^K;[FTTF-OEC'G2#_:/"C\L_G2_"?20\]YJLB@
M^6!!$?<\M^FW\S7+/WZG*?38)+!X"6(?Q2V_)?YGIMG:0V-G#;0($BA0(BCL
M`,5,X!1@1D$<BG4-]T_2NH^:NV[L^99X_)GDBSG8Q7/K@UW_`,)H-^JZA/@9
M2%4S]6S_`.RUP=]_Q_W/_75OYFO4OA+;;=+U"ZQ@R3*F?4*N?_9JXJ*O)'VV
M;5.7!/SL>C4445VGQ`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`
M!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%
M%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110!SG
MC74?[+\*7TR'$KIY2?5N/T!)_"O%-!L/[3UZQL\`B650_P#NYRWZ`UZ)\6[S
M;9:?9#_EI(TI'^Z,#_T(US?PRMA/XP1R,^3`\@]NB_\`LU<M3WJECZG+E[#+
MIUNKN_NT1[:HPH`]*6BBNH^6.'^*,RQ>%0A/,MPBC\`3_2O)]$LCJ&N6-H%#
M"29`P/\`=SS^F:]!^+=X`FFV0[L\QY],`?S-8_POTW[7XCDO&&4M(B0?]MN!
M^FZN2HN:I8^LP,OJ^6.H_-_HCV91\H^E+1176?)A1110`4444`%%%%`!1110
M`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!
M1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%
M%%`!1110`4444`%%%%`!1110`4444`%-)`!-+6/XFO3I_AR_N%.'2!]I_P!H
MC`_4BDW97*A%SFHKJ>&>(M1.K>(;Z]SE9)3L.?X!POZ`5[/X&L18>$-/7&#*
MGG-[[N1^A%>$11M-*D2<L[!1]37TK;Q+#;11)]V-0H^@&*YJ"O)L^ESV2IT:
M=&.W^2M^I-44\@A@DD/15+'\!4A/45B>+KS[%X5U*?<%/DE%)]6^4?J:Z9:)
ML^;I1YYQBNKL?/S,SL68DL3DD]S7N_@*R^P^$+%3UE4S'_@1R/TQ7B&G6;ZC
MJ5M9H#NFE6,8[9/6OI"&-((4B085%"@>@'`KGPZU;/I>(*MH0I+KK]Q-1117
M2?+A1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`444
M4`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110
M`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`'COQ6G+^([6#M';!O
MQ+-_@*D^$\>=:OI-H^6`+GTRP_P_2JGQ24CQ8A(X-JA'_?34OPOO5M_$\ENY
M`^TPE5SW8$''Y`UR?\O?F?7<K>4VCV_X+/9Z.]':N?\`%FOIX>T66XR//<;8
M5/\`$Y[X]!U-=3:2NSY2E3E4FH1W9Y1\0=2&I>+;D(<QVX$"G/\`=^]_X\37
MHWPYTHZ;X7CFD7$MVWG'/93]T?ES^->5^&]'D\0^(8;5MS*S>9.^>=@.6.?4
M]/J:^@HXUCC5$4*JC``Z`5A17-)R9[^<58T:,,'#I:_R_P`]R2BBBN@^="BB
MB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****
M`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`
M****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`0UR/Q)D*>"[I
M1_&\:_\`CX/]*ZXUQOQ,&?!\O)XEC_G45/@9U8!7Q-/U7YGD&C*'US3U/0W,
M0/\`WT*^D%^[]*^:K&X^R:A;W)!(AE23`[X(/]*^D()8YX$EC8,CJ&4CH0>0
M:QP_4]GB)/G@^FOZ$V*\\^*NIB#1[;35;Y[F3>P_V%_^N1^5=[--';Q/-(ZI
M&BEF9C@`#J37@?BG6V\1>(9KI`QCR(X%QSL'3CU)R?QJZTK1L<>389U<0JCV
MCK\^AO\`PNT@W>NR:BZYCM$PA(ZNW'Z#/YBO8ZP/!^B#0?#UO;,`)F_>S'_;
M/4?AP/PK?SBJI1Y8G/F6*^LXB4ULM%Z(6BBBM#@"BBB@`HHHH`****`"BBB@
M`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"
MBBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`**
M**`"BBB@`HHHH`****`/)OBS:%;_`$^["\/&T9;']TY`_P#'C7GMO<36MQ'<
M6\C1S1L&1U."".]>\>,=`/B'0I+:/`N$/F0L?[P[?B"17A-U:SV=S);W,+Q3
M1G#(XP0:XZT;2N?99+B(5<,J4MX]/([Z#XLWJ6@2;38I)P,>:)"JD^NW!_G7
M':QK>H>(;X3WDF]_NQQH,*@]%'^35*UM+B]N%@M89)I6.%2-22:]5\%^`3ID
MD>J:J`UV.8H`<B(^I/=OT'\DN>IH566"R].K&*YGLNO_``$:?@/PR=!TKSKA
M<7MSAI0?X!V7_'W^E=A1177&*BK(^0K5IUJCJ3W8M%%%49!1110`4444`%%%
M%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444
M`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`
M4444`%%%%`!1110`4444`%%%%`!1110`4444`-[US?CJT:[\%Z@B_>1!*/\`
M@+!C^@-=+4<L22PO$Z@JP*D'N#UI25TT:4:GLJD9KHT_N/F6NQ\._$*^T*Q%
MG-;K>0)_JP7V,@],X.1^%9/B?PW<^'=3DB9'-J6)AEQPR^F?4=Q6)7"G*+/O
MIPP^,I+F7-%ZG4^(_'6I>(8OLVT6MH?O11MDO_O-W'MQ6K\./"YO[T:Q=I_H
MT#?N58??D'?Z#^?TJIX6\`WVKSI<:A$]M8`Y.X;7E]@.P]_RS7LEM;0V=M';
MV\:QPQ@*J*,`"MJ<')\TCPLQQE'#4GAL+UWMT_X)8[4445TGS04444`%%%%`
M!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%
M%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`44
M44`%%%%`!1110`4444`%%%%`!1110`4444`)TJG=Z98WX`N[.WN,=/-B5\?F
M***3",FGH.M-/M+%-EK:P0+Z11A!^E6J**:&VV]1:***!!1110`4444`%%%%
M`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`
M%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4
M444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110!!-!%<1[)8TD4]
M0R@@_@:J6VB:592;[;3K.%_[T<"J?S`HHH:&IR6B9I8`HHHH$%%%%`!1110`
M4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1
M110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%
<%`!1110`4444`%%%%`!1110`4444`%%%%`'_V3\_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
